Vascular Biogenics Ltd (NASDAQ:VBLT) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,285,337 shares, a growth of 34.6% from the February 15th total of 954,769 shares. Approximately 15.4% of the shares of the company are sold short. Based on an average trading volume of 154,364 shares, the days-to-cover ratio is currently 8.3 days.
VBLT has been the subject of a number of research reports. Zacks Investment Research downgraded Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. HC Wainwright cut Vascular Biogenics from a “buy” rating to a “neutral” rating and set a $3.00 target price for the company. in a report on Thursday, March 8th. ValuEngine raised Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Piper Jaffray Companies cut Vascular Biogenics from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a report on Thursday, March 8th. Finally, Chardan Capital cut Vascular Biogenics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $25.00 to $3.00 in a report on Thursday, March 8th. Two research analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $3.33.
Vascular Biogenics (NASDAQ:VBLT) opened at $2.43 on Wednesday. Vascular Biogenics has a twelve month low of $2.30 and a twelve month high of $9.05. The stock has a market capitalization of $77.28, a P/E ratio of -3.07 and a beta of -2.44.
COPYRIGHT VIOLATION NOTICE: “Short Interest in Vascular Biogenics Ltd (VBLT) Increases By 34.6%” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://weekherald.com/2018/03/14/short-interest-in-vascular-biogenics-ltd-vblt-increases-by-34-6.html.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.